Vera Therapeutics

Our Company

Our mission is to change the standard of care for patients with immunologic diseases. We are developing multiple novel biologic molecules toward this end.

Our lead clinical candidate is atacicept:

  • A fusion protein that inhibits B cells and plasma cells, which can produce disease-causing antibodies
  • Potential best-in-class disease-modifying treatment for IgA Nephropathy (IgAN), an autoimmune disease that often leads to kidney failure and has few treatment options
  • In ORIGIN, a Phase 2b clinical trial for IgAN, atacicept met the primary endpoint at 24 weeks and key secondary endpoints at 36 weeks for improved kidney function
  • ORIGIN 3, a pivotal Phase 3 clinical trial, initiated June 2023
  • Target profile: self-administered subcutaneously once weekly

We are also developing MAU868:

  • A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
  • In a Phase 2 clinical trial for treatment of BK viremia in kidney transplant patients
  • No BKV-specific treatment currently available
  • Target profile: monthly IV administration

Our Team

Marshall Fordyce, MD

CEO and Founder

Celia Lin, MD

Chief Medical Officer

Lauren Frenz, MBA

Chief Business Officer

Joanne Curley, PhD

Chief Development Officer

Sean Grant, MBA

Chief Financial Officer

Tom Doan

SVP, Development Operations

Joseph Young, MBA

Chief Accounting Officer

Julien E. Capers, JD

VP, Head of Legal

Kelly Rauber

VP, Head of Human Resources

Neeraj Pakala, PhD, MBA

SVP, Product Development and Manufacturing

Board of Directors

Michael M. Morrissey, PhD

President and CEO

Andrew Cheng, MD, PhD

President and CEO
Akero Therapeutics

Beth Seidenberg, MD

General Partner
Kleiner Perkins

Maha Katabi, PhD, CFA

General Partner
Sofinnova Investments

Patrick Enright, MBA

Managing Director
Longitude Capital

Scott Morrison

Former Partner and US Life Sciences Leader

Marshall Fordyce, MD

President and CEO
Vera Therapeutics

Kimball Hall

President and CEO
Innocoll Biotherapeutics